Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma.
Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma.
适用于骨质疏松症的骨量和疼痛的改善。
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2010/11/02 | Phase 2 | UNKNOWN | |||
2009/08/18 | Phase 4 | Completed | |||
2007/10/24 | Phase 4 | Completed | |||
2005/09/14 | Phase 2 | Terminated |
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
---|
No FDA products found for this drug
Product Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
---|
No EMA products found for this drug
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval Number |
---|
No HSA products found for this drug
Product Name | Approval Number | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
---|---|---|---|---|---|---|---|---|---|
国药准字HJ20150115 | 胶囊剂 | 固力康 | 15mg | Chemical Drug | Approved | 2024/05/22 | Import | ||
国药准字HJ20150114 | 胶囊剂 | 固力康 | 15mg | Chemical Drug | Approved | 2024/05/22 | Import | ||
国药准字H20253282 | 胶囊剂 | N/A | 15mg | Chemical Drug | Approved | 2025/01/24 | Domestic | ||
国药准字J20150113 | 胶囊剂 | 固力康 | 15mg | Chemical Drug | Approved | 2020/04/01 | Import | ||
H20150114 | 胶囊剂 | 固力康 | 15mg | Chemical Drug | Expired | 2019/09/17 | Import | ||
H20150115 | 胶囊剂 | 固力康 | 15mg | Chemical Drug | Expired | 2019/09/17 | Import |
Product Name | Registration Code | Company | Category | Sale Type | Registration Date |
---|
No PPB products found for this drug
Product Name | ARTG ID | Sponsor | Status | Registration Date | Ingredient |
---|
No TGA products found for this drug